Filtered By:
Education: Study
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 82 results found since Jan 2013.
Estimating the potential impact of LDL-C lowering through SIRNA therapies on population health: A simulation study
Background and Aims: Inclisiran, an siRNA therapy, provides sustained reductions in LDL-C. Potential CV benefits of inclisiran, as an adjunct to statins, were evaluated through simulation.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: K. Ray, L. Gunn, L.G. Conde, F. Raal, R.S. Wright, N. Gosselin, L. Leiter, W. Koenig, G. Schwartz, U. Landmesser Source Type: research
Simvastatin prevents BMP-2 driven cell migration and invasion by suppressing oncogenic DNMT1 expression in breast cancer cells
This study emphasized to decipher the molecular mechanism of endogenous regulation of DNMT1 expression for finding upstream signaling molecules. Cancer database analyses found an upregulated DNMT1 expression in most cancer types including breast cancer. Overexpression of DNMT1 showed an increased cell migration, invasion, and stemness potential whereas 5-azacytidine (DNMT1 inhibitor) and siRNA mediated knockdown of DNMT1 exhibited inhibition of such cancer activities in breast cancer MDA-MB-231 and MCF-7 cells. Infact, cancer database analyses further found a positive correlation of DNMT1 transcript with both cholesterol p...
Source: Gene - July 13, 2023 Category: Genetics & Stem Cells Authors: Pooja Yadav Shreetama Bandyopadhayaya Sneha Soni Sunil Saini Lokendra K Sharma Sandeep K Shrivastava Chandi C Manda Source Type: research
Cardiac Alarmins as Residual Risk Markers of Atherosclerosis under Hypolipidemic Therapy
Int J Mol Sci. 2022 Sep 22;23(19):11174. doi: 10.3390/ijms231911174.ABSTRACTIncreased levels of low-density lipoproteins are the main risk factor in the initiation and progression of atherosclerosis. Although statin treatment can effectively lower these levels, there is still a residual risk of cardiovascular events. We hypothesize that a specific panel of stress-sensing molecules (alarmins) could indicate the persistence of silent atherosclerosis residual risk. New Zealand White rabbits were divided into: control group (C), a group that received a high-fat diet for twelve weeks (Au), and a treated hyperlipidemic group wit...
Source: Atherosclerosis - October 14, 2022 Category: Cardiology Authors: Viorel I Suica Elena Uyy Luminita Ivan Raluca M Boteanu Aurel Cerveanu-Hogas Rune Hansen Felicia Antohe Source Type: research
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
CONCLUSION: Inclisiran is an effective and safe medication for lowering LDL-C levels. Additional data regarding efficacy on cardiovascular outcomes and long-term safety profile with inclisiran are needed.PMID:35775133 | DOI:10.1177/10600280221105169
Source: The Annals of Pharmacotherapy - July 1, 2022 Category: Drugs & Pharmacology Authors: Essie Samuel Maya Watford Ugochukwu O Egolum David N Ombengi Hua Ling Drew W Cates Source Type: research
Renoprotective Effect of KLF2 on Glomerular Endothelial Dysfunction in Hypertensive Nephropathy
Cells. 2022 Feb 22;11(5):762. doi: 10.3390/cells11050762.ABSTRACTKruppel-like factor 2 (KLF2) regulates endothelial cell metabolism; endothelial dysfunction is associated with hypertension and is a predictor of atherosclerosis development and cardiovascular events. Here, we investigated the role of KLF2 in hypertensive nephropathy by regulating KLF2 expression in human primary glomerular endothelial cells (hPGECs) and evaluating this expression in the kidney tissues of a 5/6 nephrectomy mouse model as well as patients with hypertension. Hypertension-mimicking devices and KLF2 siRNA were used to downregulate KLF2 expression...
Source: Atherosclerosis - March 10, 2022 Category: Cardiology Authors: Eunjin Bae Mi-Yeon Yu Jong-Joo Moon Ji-Eun Kim Saram Lee Sang-Woong Han Dong-Jun Park Yon-Su Kim Seung-Hee Yang Source Type: research
The multifaceted biology of PCSK9
This article reviews the discovery of PCSK9, its structure-function characteristics, and its presently known and proposed novel biological functions. The major critical function of PCSK9 deduced from human and mouse studies, as well as cellular and structural analyses, is its role in increasing the levels of circulating LDL-cholesterol (LDLc), via its ability to enhance the sorting and escort of the cell surface LDL receptor (LDLR) to lysosomes. This implicates the binding of the catalytic domain of PCSK9 to the EGF-A domain of the LDLR. This also requires the presence of the C-terminal Cys/His-rich domain (CHRD), its bind...
Source: Endocrine Reviews - October 9, 2021 Category: Endocrinology Authors: Nabil G Seidah Annik Prat Source Type: research
